The researchers explored the use of THZ1, a selective CDK7 inhibitor, known to disrupt the function of transcriptional kinases. By targeting the super-enhancer landscapes associated with SKIL, they demonstrated a significant reduction in gastric cancer cell proliferation. This approach is particularly compelling as it addresses the underpinnings of cancer at a foundational level—by inhibiting dysregulated transcription rather than merely targeting downstream effects.

In their experimental framework, the team employed a series of in vitro assays to quantify the expression levels of SKIL post-treatment with THZ1. The data revealed a stark decrease in SKIL transcription, corroborated by diminished cellular viability. This reduction highlights the potential of THZ1 in mitigating the aggressive nature of gastric cancer by effectively crippling a central regulatory node in the cancer’s genetic expression machinery.

The study also delves into the complexity of the molecular interactions at play within the super-enhancer regions. Super-enhancers are defined as large clusters of transcriptional enhancers that drive the expression of key oncogenes and are often found at the nexus of various signaling pathways. By delineating the impact of CDK7 inhibition on these super-enhancers, the authors provided new insights into how alterations in transcriptional control can influence tumor behavior.

Interestingly, the implications of this research extend beyond gastric cancer. The methodology developed could serve as a blueprint for tackling other malignancies characterized by super-enhancer-driven transcriptional networks. This convergence of cancer genomics and therapeutic intervention indicates a paradigm shift in the design of targeted cancer therapies.

Furthermore, the paper discusses the potential side effects of CDK7 inhibitors, which have been reported in various preclinical models. The authors suggest that a careful balancing act will be necessary to maximize therapeutic efficacy while minimizing adverse effects. By integrating this research into ongoing clinical trials for CDK7 inhibitors, the development of more refined and effective cancer therapies can be achieved.

As the study unfolds, it poses critical questions about the future of cancer treatment modalities. Will CDK7 inhibitors like THZ1 pave the way for new standards in managing gastric cancer? Or will they become just another tool in an ever-expanding arsenal of cancer therapeutics?

The rigorous experimental design and the necessity for further exploration into the mechanisms governing super-enhancer activity posit exciting directions for future research. Moving forward, the integration of genomic data with clinical outcomes will be crucial for the successful application of these findings in real-world clinical scenarios.

Moreover, the authors advocate for a multi-targeted approach to cancer therapy, recognizing that single-agent strategies may not suffice in overcoming the complexities of tumor biology. This perspective heralds a shift towards combination therapies that synergistically enhance the therapeutic window and combat resistance mechanisms.

The findings presented in this study not only add a significant piece to the puzzle of gastric cancer treatment but also emphasize the potential of transcriptional regulation as a therapeutic target in various cancers. With the intricate interplay of oncogenic drivers and regulatory elements illuminated by this research, the path towards more effective therapeutic strategies appears promising.

Ultimately, the study by Lan et al. signals a transformative step in the ongoing battle against gastric cancer. By identifying CDK7 as a pivotal player in super-enhancer-driven tumor progression, they provide compelling evidence that supports a focused exploration of transcriptional inhibition as a valid therapeutic avenue. The convergence of molecular biology and targeted therapy in this research highlights the possibilities that lie ahead in cancer treatment paradigms.

As the scientific community strives towards innovative solutions to combat cancer, these findings underscore the necessity for continued investment in understanding the fundamental biology of cancer. The potential for enhanced treatment options rests on the integration of cutting-edge research with clinical application, which this study exemplifies eloquently.

In conclusion, targeting super-enhancer-driven transcription presents a novel and promising approach in the fight against gastric cancer. Through the inhibition of CDK7 by THZ1, the authors unveil a path forward that could significantly alter therapeutic landscapes and improve patient outcomes. As researchers are armed with this knowledge, the hopeful prospect of curbing the tide of gastric cancer becomes increasingly tangible and transformative.

Subject of Research: Gastric cancer and CDK7 inhibition

Article Title: Targeting super-enhancer-driven SKIL transcription by CDK7 inhibitor THZ1 to suppress gastric cancer progression

Article References:

Lan, B., Zhou, T., Pan, L. et al. Targeting super-enhancer-driven SKIL transcription by CDK7 inhibitor THZ1 to suppress gastric cancer progression.
J Transl Med (2026). https://doi.org/10.1186/s12967-026-07721-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-07721-1

Keywords: gastric cancer, CDK7 inhibitor, THZ1, super-enhancers, transcription regulation

Lung cancer remains one of the deadliest cancers worldwide, in part due to its ability to develop resistance to conventional therapies like cisplatin. The current research addressed this critical hurdle by exploring how epigenetic modulators such as chidamide influence cancer cell survival mechanisms. Prior to this investigation, the detailed mechanisms underlying chidamide’s role in lung cancer, especially regarding metabolic pathways like glycolysis and cell death pathways such as ferroptosis, were poorly understood.

Using a battery of in vitro assays including Cell Counting Kit-8 for cell viability and half maximal inhibitory concentration (IC50) determinations, the research team systematically evaluated how chidamide affects lung cancer cell proliferation. They found that chidamide markedly diminishes the viability of these cancer cells, suggesting potent growth-inhibitory effects.

One of the striking findings relates to chidamide’s impact on cancer metabolism. The researchers measured glucose uptake, lactate production, and intracellular ATP levels—hallmarks of glycolytic activity—and demonstrated that chidamide effectively disrupts glycolysis in lung cancer cells. Since glycolysis is a primary energy source driving tumor growth under hypoxic conditions, its inhibition could severely impair tumor survival and progression.

Beyond metabolism, the study delves into the realm of ferroptosis, a form of regulated cell death associated with iron-dependent lipid peroxidation. By measuring reactive oxygen species (ROS), glutathione levels, and ferrous ion (Fe2+) accumulation, the investigators confirmed that chidamide fosters a cellular environment favoring ferroptosis. This is particularly noteworthy because ferroptosis is emerging as a critical vulnerability to exploit in cancer therapeutics, especially in tumors that have become resistant to apoptosis.

Central to these processes is USP35, a deubiquitinating enzyme identified here as a molecular target of chidamide. The authors demonstrate that chidamide binds to USP35 and reduces its protein expression in lung cancer cells. This downregulation appears to mediate the suppression of glycolysis and promotion of ferroptosis, uncovering a novel pathway by which chidamide exerts its anti-cancer effects.

The interplay between USP35 and cisplatin sensitivity was also explored. Owing to its role in regulating protein stability, USP35’s suppression by chidamide was linked to enhanced susceptibility of lung cancer cells to cisplatin. This was validated through colony formation assays and flow cytometry, revealing that chidamide not only impairs growth but also sensitizes cancer cells to this frontline chemotherapeutic agent.

Translating these findings from the bench to in vivo models, the team employed tumor xenograft assays in mice, which confirmed that chidamide treatments significantly curtailed tumor growth. Furthermore, the combination of chidamide and cisplatin yielded additive effects, markedly increasing tumor sensitivity to cisplatin, which could herald new combination treatment strategies.

This comprehensive study, therefore, establishes chidamide as a potent adjunct in lung cancer therapy, functioning through dual mechanisms that cripple tumor metabolism and trigger ferroptotic cell death. By targeting USP35, chidamide not only stalls tumor progression but also restores chemosensitivity, offering renewed hope against lung cancer’s notorious treatment resistance.

Understanding the mechanistic intricacies of histone deacetylase inhibitors such as chidamide may be instrumental in crafting future lung cancer treatments. The modulation of metabolic pathways like glycolysis and cell death pathways like ferroptosis could present new therapeutic windows, particularly in tumors refractory to current standards of care.

While further clinical validation is necessary, this study lays a robust foundation for developing combination therapies that exploit metabolic and epigenetic vulnerabilities in lung cancer. The targeting of USP35, a previously underexplored deubiquitinase, opens a novel avenue that might also extend to other cancers exhibiting similar resistance profiles.

In summary, chidamide emerges as a promising candidate not just for impairing lung cancer cell survival through blocking glycolysis, but also for enhancing vulnerability via ferroptosis and improving the effectiveness of cisplatin chemotherapy. These findings underscore the importance of integrating targeted molecular approaches with conventional treatments to overcome lung cancer’s adaptive resilience.

As the scientific community continues to unravel the complexities of tumor biology, such multidimensional therapeutic strategies could revolutionize treatment paradigms, potentially improving survival outcomes for patients afflicted with notoriously aggressive forms of lung cancer.

This study serves as a compelling example of how epigenetic drugs, metabolic modulators, and cell death mechanisms intersect, and sets the stage for the next generation of lung cancer therapies that are both more precise and more effective.

Subject of Research: Molecular mechanisms underlying chidamide’s effects on glycolysis, ferroptosis, and cisplatin sensitivity in lung cancer cells.

Article Title: Chidamide impedes glycolysis but increases ferroptosis and cisplatin sensitivity of lung cancer cells through downregulating USP35.

Article References:
Wang, K., An, L., Zang, A. et al. Chidamide impedes glycolysis but increases ferroptosis and cisplatin sensitivity of lung cancer cells through downregulating USP35. BMC Cancer 25, 1504 (2025). https://doi.org/10.1186/s12885-025-14925-z

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14925-z